source
- Erasca reports 44% response in KRAS-mutated pancreatic cancer, eyes Phase 3 trialErasca announced that 44% of patients with KRAS-mutated pancreatic cancer showed a response to its experimental drug ERAS-0015 in a small Phase 1 study. The company said the treatment was well tole…
- Revolution Medicines reports strong data for KRAS-targeted pancreatic cancer drug amid rising competitionRevolution Medicines presented encouraging results for its KRAS‑targeted therapy aimed at pancreatic cancer at a recent industry meeting. The company highlighted the potency of the drug in preclini…